Description
Advanced Multi-Targeted Depigmenting Formula
Hydroquinone-based. Designed for melasma, PIH, and uneven pigmentation
Product Overview
Lucida Pigment Cream Plus is a physician-formulated cream designed to treat melasma, post-inflammatory hyperpigmentation (PIH), and UV-induced dark spots by targeting multiple biological pathways of melanogenesis. The formulation combines Hydroquinone, a gold-standard tyrosinase inhibitor, with Tranexamic Acid, Vitamin C, and Glycolic Acid to suppress pigment formation, exfoliate dyschromic cells, and reduce inflammatory triggers of melanocyte activation.
This multi-functional approach makes Lucida an ideal choice for short-term intensive protocols or as part of staged treatment plans for persistent pigmentary disorders.
Core Mechanisms of Action
-
Hydroquinone (HQ):
Inhibits tyrosinase, the rate-limiting enzyme in melanin production. HQ is most effective in treating epidermal pigmentation and has rapid onset of action in reducing hyperchromia. -
Tranexamic Acid (TA):
Reduces UV- and inflammation-induced pigmentation by interfering with the plasminogen activation system. TA downregulates prostaglandins and arachidonic acid pathways, indirectly reducing melanocyte overactivity. -
Vitamin C (L-Ascorbic Acid or derivative):
A potent antioxidant that scavenges reactive oxygen species (ROS), slows melanin synthesis, and improves collagen quality. It also enhances skin luminosity. -
Glycolic Acid (AHA):
Improves epidermal turnover, facilitates penetration of depigmenting agents, and accelerates the shedding of pigmented keratinocytes. Supports mild resurfacing and skin texture refinement.
Clinical Indications
-
Epidermal melasma (symmetric, light-to-moderate depth)
-
Post-inflammatory hyperpigmentation (acne, friction, burns, cosmetic irritation)
-
Sun-induced lentigines and photodamage
-
Adjuvant use in protocols including laser toning, microneedling, and chemical peels
-
Early-stage pigmentation in combination with oral TA (under specialist care)
Recommended Use in Clinical Settings
-
Application:
Apply once daily at night on cleansed, dry skin. Spot-treat on pigmented areas or apply to the full face depending on the distribution of lesions. -
Duration:
Use for a maximum of 12–16 weeks as part of a pigment correction phase. Follow with a maintenance regimen using non-HQ brighteners (e.g., arbutin, niacinamide, kojic acid). -
Sunscreen:
A broad-spectrum SPF 50+ is mandatory in the morning and throughout the day to prevent rebound pigmentation and irritation. -
Titration & Monitoring:
Start every other night in sensitive patients (Fitzpatrick IV–VI), increase to nightly as tolerated. Assess response at 4, 8, and 12 weeks.
Clinical Tips for Optimal Use
-
Pair with barrier-strengthening moisturizers in patients with dry or reactive skin
-
Can be layered with in-office TA mesotherapy or combined with oral TA for faster results
-
Avoid concurrent use with strong retinoids or acids unless on a staggered schedule
-
Consider stopping HQ temporarily before chemical peels or laser treatments to reduce irritation risk
Contraindications
-
Pregnancy and breastfeeding
-
History of exogenous ochronosis or HQ allergy
-
Active eczema, barrier impairment, or open wounds in treatment area
-
Recent chemical exfoliation or resurfacing procedures (wait 7–14 days minimum)
Expected Skin Reactions
-
Mild peeling, tingling, dryness, or redness during the first 1–3 weeks
-
Temporary worsening of pigmentation may occur before improvement
-
In rare cases: irritation-induced rebound PIH or contact dermatitis
→ If observed, reduce frequency or pause until barrier stabilizes
Key Ingredients
Actives:
-
Hydroquinone (2% or 4%, depending on local regulations)
-
Tranexamic Acid
-
Vitamin C (stabilized form)
-
Glycolic Acid
Vehicle base includes:
-
Emollients, pH regulators, absorption enhancers, non-sensitizing preservatives.
Reviews
There are no reviews yet.